tetano
Editor, Senior Moderator
Endocr Metab Immune Disord Drug Targets
. 2022 Jun 23.
doi: 10.2174/1871530322666220623121922. Online ahead of print.
The Role of Soluble ACE2 as a Prognostic Marker in Severe COVID-19: A Brief Meta-Analysis
Nadereh Naderi[SUP] 1 [/SUP], Mahsa Rahimzadeh[SUP] 2 3 [/SUP]
Affiliations
Abstract
Background: The recently emerged novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has posed a serious threat to public health, and there is an urgent need to establish tools that can aid the clinician in the evaluation and management of high-risk patients. This meta-analysis aimed to investigate the potential of sACE2 (soluble angiotensin-converting enzyme 2) as a prognostic biomarker in COVID-19.
Method: A comprehensive search of PubMed/MEDLINE, Cochrane, and Google Scholar, was performed until May 26, 2021. Data extraction and quality assessment of the study were independently conducted by authors. Finally, 6 studies were included in this meta-analysis.
Results: ACE-2 serum or plasma levels compared between COVID-19 patients and healthy controls. ACE-2 level was not significantly different between severe COVID-19 patients and healthy controls (SMD= 1.2; 95% CI: -1.3-1.5; P=0.86), severe and non-severe COVID-19 patients (SMD= 0.3; 95% CI: -0.06-0.7; P=0.1) and severe COVID-19 patients and healthy controls (SMD= 0.6; 95% CI: -1.1-2.3; P=0.5).
Conclusions: We cautiously propose that circulating levels of ACE2 cannot be used as a biomarker to assess disease severity in COVID-19 patients.
Keywords: ACE2; COVID-19; angiotensin-converting enzyme 2; biomarkers.
. 2022 Jun 23.
doi: 10.2174/1871530322666220623121922. Online ahead of print.
The Role of Soluble ACE2 as a Prognostic Marker in Severe COVID-19: A Brief Meta-Analysis
Nadereh Naderi[SUP] 1 [/SUP], Mahsa Rahimzadeh[SUP] 2 3 [/SUP]
Affiliations
- PMID: 35747972
- DOI: 10.2174/1871530322666220623121922
Abstract
Background: The recently emerged novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has posed a serious threat to public health, and there is an urgent need to establish tools that can aid the clinician in the evaluation and management of high-risk patients. This meta-analysis aimed to investigate the potential of sACE2 (soluble angiotensin-converting enzyme 2) as a prognostic biomarker in COVID-19.
Method: A comprehensive search of PubMed/MEDLINE, Cochrane, and Google Scholar, was performed until May 26, 2021. Data extraction and quality assessment of the study were independently conducted by authors. Finally, 6 studies were included in this meta-analysis.
Results: ACE-2 serum or plasma levels compared between COVID-19 patients and healthy controls. ACE-2 level was not significantly different between severe COVID-19 patients and healthy controls (SMD= 1.2; 95% CI: -1.3-1.5; P=0.86), severe and non-severe COVID-19 patients (SMD= 0.3; 95% CI: -0.06-0.7; P=0.1) and severe COVID-19 patients and healthy controls (SMD= 0.6; 95% CI: -1.1-2.3; P=0.5).
Conclusions: We cautiously propose that circulating levels of ACE2 cannot be used as a biomarker to assess disease severity in COVID-19 patients.
Keywords: ACE2; COVID-19; angiotensin-converting enzyme 2; biomarkers.